Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 10;14:746. doi: 10.1038/s41467-023-36334-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Tumor analysis in MTO-injected C57BL/6J mice treated with oxaliplatin. Left panel: percentage of tumor growth upon treatment. Right panels: percentage of CD31, CD45 and α-SMA intratumoral positivity. Control (blue; n = 5) and treated conditions (red; n = 8). Values are mean ± sd. p values are indicated. Drawing modified from Tauriello et al.¹⁷. b Biological activity of oxaliplatin against HT29-M6, PDO and CCD-18Co. Values are mean ± sd. EC₅₀ are indicated. Representative of n = 3 biologically independent experiments. c 12-days follow-up of HT29-M6 and CCD-18Co cells survival upon oxaliplatin treatment. n = 3 biologically independent experiments. Values are mean ± sd. p value is indicated. d Oxaliplatin uptake in HT29-M6 (CRC) after 4 h treatment and in CCD-18Co (Fib) after 4 h treatment and 90 days after treatment. n = 6 biologically independent experiments. Mean quantities ± sd and p value are indicated. e Oxaliplatin biodistribution representative of eight independent patient tumors resected after CT. Time post CT is indicated. Left panels: platinum (Pt) uptake map. Right panels: corresponding hematoxylin and eosin staining, Scale bars: 100 μm. Drawing modified from Rivas, Linares et al.⁷⁸. f Mean stromal (red) and cancer (blue) Pt uptake in samples from eight CRC patients. p value is indicated. PDO patient-derived tumor organoids, C cancer, S stroma, CT chemotherapy, cps count per second. Two-sided, unpaired (a, c, d) and paired (f) t-test p values (p) are indicated. Source data are provided as a Source Data file.